Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06351345
PHASE2

129 Xenon Imaging in Patients Treated With Sotatercept

Sponsor: Bastiaan Driehuys

View on ClinicalTrials.gov

Summary

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

Official title: 129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

14

Start Date

2025-10-27

Completion Date

2030-02-04

Last Updated

2026-02-24

Healthy Volunteers

No

Interventions

DRUG

129Xe Hyperpolarized

Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).

Locations (1)

Duke University Medical Center

Durham, North Carolina, United States